What is SCORAD?
SCORAD (SCORing Atopic Dermatitis) is a clinical tool developed by the European Task Force on Atopic Dermatitis in 1993 to standardize the assessment of eczema severity. It combines three dimensions — the extent of disease (body surface area affected), the intensity of specific lesion types, and the patient's own assessment of subjective symptoms — into a single composite index ranging from 0 to 103.
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease, affecting up to 20% of children and 3% of adults worldwide. Objective severity scoring is crucial for treatment decisions, monitoring response to therapy, and clinical research. SCORAD is one of the most validated and widely used instruments for this purpose, alongside EASI (Eczema Area and Severity Index) and POEM (Patient-Oriented Eczema Measure).
Unlike some other scoring systems, SCORAD uniquely incorporates the patient's perspective through its subjective symptom component, making it a more holistic measure of disease burden.
SCORAD Formula
Where:
- A = Extent (% of body surface area affected, 0–100)
- B = Intensity (sum of 6 items, each scored 0–3, total 0–18)
- C = Subjective symptoms (sum of 2 items on visual analog scale 0–10, total 0–20)
Severity Classification
| SCORAD Range | Severity | Clinical Implication |
|---|---|---|
| < 25 | Mild | Emollients + topical therapy as needed |
| 25 – 50 | Moderate | Regular topical corticosteroids / calcineurin inhibitors |
| > 50 | Severe | Consider systemic therapy (immunosuppressants, biologics) |
SCORAD Components Explained
A — Extent (Body Surface Area)
The extent is assessed using the Rule of Nines (similar to burn assessment) or by marking affected areas on a body diagram. Each body region has a defined percentage:
| Body Region | % BSA (Adults) | % BSA (Children <2 yr) |
|---|---|---|
| Head & Neck | 9% | 18% |
| Each Upper Limb | 9% | 9% |
| Anterior Trunk | 18% | 18% |
| Posterior Trunk | 18% | 18% |
| Each Lower Limb | 18% | 13.5% |
| Perineum | 1% | 1% |
B — Intensity Items
Six morphological features are each graded on a 0–3 scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe):
| Item | Description | Score Range |
|---|---|---|
| Erythema | Redness of the skin | 0–3 |
| Edema / Papulation | Swelling or raised papules | 0–3 |
| Oozing / Crusts | Weeping or crusted lesions | 0–3 |
| Excoriation | Scratch marks | 0–3 |
| Lichenification | Skin thickening from chronic scratching | 0–3 |
| Dryness | Assessed on uninvolved skin | 0–3 |
C — Subjective Symptoms
Patients rate two symptoms over the last 3 days/nights using a visual analog scale (0–10):
- Pruritus (Itch): 0 = no itch, 10 = worst imaginable itch
- Sleep loss: 0 = no sleep disturbance, 10 = complete insomnia due to eczema
Severity Scale Diagram
Treatment Algorithms by Severity
The SCORAD index directly informs a stepwise approach to atopic dermatitis management, as recommended by international guidelines:
Mild AD (SCORAD < 25)
- Daily emollients/moisturizers as baseline therapy
- Low-potency topical corticosteroids (TCS) for flares
- Trigger avoidance (irritants, allergens, stress)
- Patient education on skin care routines
Moderate AD (SCORAD 25–50)
- Continued emollient use
- Medium-potency TCS or topical calcineurin inhibitors (TCI: tacrolimus, pimecrolimus)
- Proactive (maintenance) therapy with TCS/TCI on previously affected areas
- Wet wrap therapy for resistant areas
- Consideration of phototherapy (narrowband UVB)
Severe AD (SCORAD > 50)
- All the above measures intensified
- Systemic immunosuppressants: cyclosporine, methotrexate, azathioprine, mycophenolate
- Biologic therapy: dupilumab (anti-IL-4Rα), tralokinumab (anti-IL-13)
- JAK inhibitors: baricitinib, upadacitinib, abrocitinib
- Multidisciplinary management (dermatology, allergy, psychology)
Worked Example
A 28-year-old patient presents with atopic dermatitis. Assessment findings:
- Extent: 35% BSA affected (face, antecubital fossae, popliteal fossae, hands)
- Intensity: Erythema 2, Edema 1, Oozing 1, Excoriation 2, Lichenification 2, Dryness 2 → B = 10
- Subjective: Pruritus 7/10, Sleep loss 5/10 → C = 12
This patient falls into the severe category, indicating the need for systemic therapy in addition to optimized topical treatment.
Frequently Asked Questions
What is the difference between SCORAD and Objective SCORAD?
Objective SCORAD (oSCORAD) excludes the subjective component C (pruritus and sleep loss), calculated as A/5 + 7B/2. It ranges from 0 to 83 and is useful when patient-reported outcomes are unreliable (e.g., infants, cognitively impaired patients). The same severity thresholds are approximately <15 mild, 15–40 moderate, and >40 severe for oSCORAD.
How often should SCORAD be measured?
In clinical trials, SCORAD is typically assessed at baseline and at regular follow-up intervals (e.g., every 2–4 weeks). In clinical practice, it should be measured at each visit to track treatment response. A reduction of 8.7 points or more is considered a clinically meaningful change (the minimal clinically important difference, or MCID).
Can SCORAD be used for children?
Yes, SCORAD is validated for all age groups. However, the BSA estimation in young children uses a modified Rule of Nines (the head represents 18% of BSA in infants vs. 9% in adults). The subjective symptom assessment may require parental proxy reporting in young children.
How does SCORAD compare to EASI?
EASI (Eczema Area and Severity Index) assesses only objective signs (erythema, induration/papulation, excoriation, lichenification) across four body regions. It does not include dryness, oozing/crusts, or subjective symptoms. EASI is now the preferred primary endpoint in many clinical trials, while SCORAD remains popular in European clinical practice due to its inclusion of subjective symptoms.
What about SCORAD-D and PO-SCORAD?
SCORAD-D is a simplified version focusing on selected parameters. PO-SCORAD (Patient-Oriented SCORAD) is a self-assessment version where patients evaluate their own disease at home, using standardized photos for reference. It has shown good correlation with physician-assessed SCORAD and is valuable for telemedicine and home monitoring.